hVivo's chairman Cathal Friel not seeking re-election Irish research and clinical trial specialist hVivo said today that its chairman Cathal Friel does not intend to seek re-election to its board at its AGM later this year. Business • 10 Apr
hVivo's chairman Cathal Friel not seeking re-election Irish research and clinical trial specialist hVivo said today that its chairman Cathal Friel does not intend to seek re-election to its board at its AGM later this year. Business • 10 Apr
Clinical trial specialist hVivo's H1 revenues jump by 30% Irish research and clinical trial specialist hVivo saw its revenues rise by over 30% in the first six months of the year to reach £35.6m. Business • 10 Sep 24
Clinical trial specialist hVivo's H1 revenues jump by 30% Irish research and clinical trial specialist hVivo saw its revenues rise by over 30% in the first six months of the year to reach £35.6m. Business • 10 Sep 24
hVivo expects half year revenues to rise by 30% Healthcare company hVIVO, formerly Open Orphan, said it expects to report first half revenues of £35.6m, which would represent 30.6% revenue growth on the same time last year Business • 17 Jul 24
hVivo expects half year revenues to rise by 30% Healthcare company hVIVO, formerly Open Orphan, said it expects to report first half revenues of £35.6m, which would represent 30.6% revenue growth on the same time last year Business • 17 Jul 24
hVIVO reports higher profits and revenues for 2023 Healthcare company hVIVO, formerly Open Orphan, has reported higher revenues and earnings for 2023 and said it had a robust orderbook for this year. Business • 09 Apr 24
hVIVO reports higher profits and revenues for 2023 Healthcare company hVIVO, formerly Open Orphan, has reported higher revenues and earnings for 2023 and said it had a robust orderbook for this year. Business • 09 Apr 24
hVIVO's 2023 revenues rise by 15.5% Healthcare company hVIVO, formerly Open Orphan, said today it expects to report full year revenues of £56m for 2023, a 15.5% increase on the £48.5m reported in 2022. Business • 30 Jan 24
hVIVO's 2023 revenues rise by 15.5% Healthcare company hVIVO, formerly Open Orphan, said today it expects to report full year revenues of £56m for 2023, a 15.5% increase on the £48.5m reported in 2022. Business • 30 Jan 24
hVIVO reports surge in half year revenues as HCTs rise hVIVO, formerly Open Orphan, has today reported a jump in revenues and earnings for the six months to the end of June and said its outlook for the full year was "extremely positive". Business • 12 Sep 23
hVIVO reports surge in half year revenues as HCTs rise hVIVO, formerly Open Orphan, has today reported a jump in revenues and earnings for the six months to the end of June and said its outlook for the full year was "extremely positive". Business • 12 Sep 23
Open Orphan's hVIVO wins RSV human challenge study deal Specialist pharmaceutical services clinical research company Open Orphan said its hVIVO subsidiary has signed a £5.1m contract with a biopharmaceutical company to use its respiratory syncytial virus (RSV) human challenge study model. Business • 17 Nov 21
Open Orphan's hVIVO wins RSV human challenge study deal Specialist pharmaceutical services clinical research company Open Orphan said its hVIVO subsidiary has signed a £5.1m contract with a biopharmaceutical company to use its respiratory syncytial virus (RSV) human challenge study model. Business • 17 Nov 21
Open Orphan agrees Covid contract with UK government Dublin-listed pharmaceutical company Open Orphan said its subsidary hVIVO has agreed a deal with the UK government to develop a Covid-19 human challenge study model. Business • 20 Oct 20
Open Orphan agrees Covid contract with UK government Dublin-listed pharmaceutical company Open Orphan said its subsidary hVIVO has agreed a deal with the UK government to develop a Covid-19 human challenge study model. Business • 20 Oct 20
Open Orphan says outlook 'has never been stronger' Dublin-listed pharmaceutical company Open Orphan has reported an operating loss of £5m for the six months to the end of June but said its business outlook has never been stronger. Business • 30 Sep 20
Open Orphan says outlook 'has never been stronger' Dublin-listed pharmaceutical company Open Orphan has reported an operating loss of £5m for the six months to the end of June but said its business outlook has never been stronger. Business • 30 Sep 20
Open Orphan wins new £4.3m challenge study deal Dublin-listed pharmaceutical company Open Orphan has announced a new £4.3m contract to conduct a human viral challenge study using one of its eight traditional challenge study models for another of the global top 10 vaccine companies. Business • 28 Sep 20
Open Orphan wins new £4.3m challenge study deal Dublin-listed pharmaceutical company Open Orphan has announced a new £4.3m contract to conduct a human viral challenge study using one of its eight traditional challenge study models for another of the global top 10 vaccine companies. Business • 28 Sep 20
Open Orphan to buy hVIVO in £30m merger deal Irish pharmaceutical firm Open Orphan has agreed to a merger deal with British firm hVIVO, which would create a group valued at around £30m. Business • 09 Dec 19
Open Orphan to buy hVIVO in £30m merger deal Irish pharmaceutical firm Open Orphan has agreed to a merger deal with British firm hVIVO, which would create a group valued at around £30m. Business • 09 Dec 19
